Successful first “Aeson® European User Meeting”, marking an important step in the deployment of CARMAT’s artificial heart

Paris, April 22, 2022 – 6 pm CEST

CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure, today announced the publication of the Company’s Universal registration document for the year ended December 31, 2021.

The document, filed with the French stock-market authority (Autorité des Marchés Financiers) on April 21, 2022, is available to the public free of charge upon request, as per current legal regulations; and on the Company’s website under the section Investors / Documentation / Regulated information, as well as on that of the AMF (www.amf-france.org).

It notably includes the 2021 annual financial report, the report on corporate governance, the required information in relation to the share repurchase program, as well as the auditors’ reports and information on the fees paid to the statutory auditors in 2021.

Paris, April 12, 2022 – 8.00 am (CEST)

CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative to people suffering from end-stage biventricular heart failure (the “Company”), today announces the success of its capital increase for a gross amount of €40.5 million, of which €36.5 million for specialized and strategic investors as defined below and €4.1 million for individuals (via the PrimaryBid platform) (the “Global Offering”).

Stéphane Piat, Chief Executive Office of CARMAT, said: “I would like to thank all of our investors, both historical and new, for their contribution to the success of this important financing for CARMAT. The funds raised will allow us to calmly focus, during the coming months, on the resumption of implants of our Aeson® artificial heart, expected in October 2022. I am particularly delighted with the participation of a large number of individual investors, made possible thanks to the PrimaryBid platform. We are very appreciative of their support for CARMAT, a unique French company in the field of medical technologies. Thanks to their support and that of all our other investors, we are one step closer to our goal of making Aeson® the number 1 alternative to a heart transplant, and thus of providing a genuine solution for the many patients suffering from end-stage biventricular heart failure who currently have no therapeutic options.”

• Global Offering aimed at specialized and strategic investors, as well as individual investors via the PrimaryBid platform
• Issue price of new shares at 10.0 euros per share
• Closing of the Primary Bid Offering on April 11, 2022 at 10 pm and of the Reserved Offering on April 12, 2022 before market opening

Paris, April 11, 2022 – 5.45 pm (CEST)

CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative to people suffering from end-stage biventricular heart failure (the “Company”), today announces the launch of a c. 30 million euros capital increase via the issuance of new shares at a fixed price of 10.0 euros per share aimed at specialized and strategic investors, as defined below, and at individuals (via the PrimaryBid platform) (the “Global Offering”).

The Company is planning to use the funds raised through this Global Offering to ensure the continuity of its activities, and notably to support the restart of the production of its Aeson® artificial heart and ensure the resumption – scheduled for October 2022 – of its implants, both from a commercial standpoint and within the framework of its clinical trials.

Stéphane Piat, Chief Executive Officer of CARMAT, commented: “The funds raised via the operation we are launching today will strengthen our financial structure and allow us to calmly ensure the resumption of implants of our Aeson® artificial heart from October 2022. Indeed, the constructive dialogue we are having with the competent authorities and the notified body DEKRA, as well as the recent restarting of our production, following the incorporation of changes enabling us to strengthen the sturdiness of the various components, give us confidence in our ability to resume our clinical trials and sales as expected and thus address the strong expectations of physicians and patients. The support of our longstanding shareholders is particularly important during this crucial period for the Company, and I would particularly like to emphasize their substantial commitment. I am also pleased that we are able to offer other investors, as well as individuals – via the PrimaryBid system – the possibility of contributing to the development of our Company and its unique technology that we more than ever feel has the potential to radically and lastingly change the care and treatment provided to patients with end-stage biventricular heart failure”.